查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2005192

间质干细胞/治疗讯号细胞（MSCs）：进展与应用（2026）

Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2026
出版日期: | 出版商: BioInformant | 英文 381 Pages | 订单完成后即时交付

价格
简介目录

执行摘要

间质干细胞（MSCs）是多功能细胞，也被称为间质干细胞、治疗性讯号细胞或间质支持细胞，这反映了它们的多功能性和广泛的应用。 MSCs可以分化成多种细胞类型，包括成骨细胞、软骨细胞、肌肉细胞和脂肪细胞。由于其独特的分泌促进组织修復因子以及透过抗发炎和抗纤维化作用调节微环境的能力，MSCs在再生医学中不可或缺。此外，其免疫逃脱特性使MSCs特别适用于同种异体移植。

间质干细胞是众多产业的重要原料，包括再生医学、药用化妆品和培养肉生产。主要应用领域包括：

  • 细胞疗法用于治疗肌肉骨骼疾病、脊髓损伤和心血管疾病。
  • 人造组织和器官，如皮肤、骨骼、血管和肝臟。
  • 细胞衍生产品，如外泌体和生长因子，被用于化妆品和护肤品中。
  • MSCs在肌肉发育和培养肉生产中的作用，利用其分化成肌肉细胞和脂肪细胞的能力。

在全球范围内，已有 12 种使用间质干细胞 (MSC)的治疗方法核准用于各种适应症，其中大部分集中在韩国、日本和欧盟。

具体而言，韩国已核准五种产品上市：Anterogen公司的「Queencell」、Pharmicell公司的「Cellgram AMI」和「Cupistem」、Medipost公司的「Cartistem」以及Corestem公司的「NeuroNata®」。日本已核准两种产品上市：JCR Pharmaceuticals公司的「​​Temcell HS」和Nipro Corporation公司的「Stemirac」。欧洲药品管理局（EMA）已核准两种产品上市：Chiesi Farmaceutici公司的「Holoclar」和TiGenix/Takeda公司的「Alofisel」。印度已批准产品上市：Stempeutics公司的「​​Stempeucel」。伊朗已批准一种产品核可产品核可：Cell Tech Pharmae​​d公司开发的「MesestroCell」。最后，澳洲已产品核可：Mesoblast公司的「Remestemcel-L」。

儘管取得了这些进展，但目前还没有任何基于 MSC（间质干细胞）的疗法获得美国 FDA 的核准，儘管 FDA 正在积极审查 Mesoblast 的「Remestemcel-L」。

在药用化妆品市场，间质干细胞（MSC）衍生产品，尤其是外泌体，因其抗衰老龄化和再生特性而迅速走红，欧莱雅和强生等公司已在该领域投入巨资。同样，培养肉公司也利用MSC生产肌肉和脂肪细胞，以改善口感和质地。 Upside Foods和Good Meat等公司的人造鸡肉等突破性核准，为该行业的进一步发展铺平了道路。

利用间质干细胞的基因编辑技术也不断发展，使得过度表现抗肿瘤基因和治疗因子成为可能。研究人员也正在探索将间质干细胞应用于3D列印和人工器官製造，预计未来十年将取得突破性进展。

值得注意的是，像Cynata Therapeutics这样的公司率先开发了iPS细胞衍生的间质干细胞（MSC）生产技术，从而实现了大规模的治疗药物开发。目前，至少有八家公司参与了iPS细胞衍生的MSC（iMSC）疗法的研发，其中包括Cynata Therapeutics、Eterna Therapeutics、Implant Therapeutics、Bone Therapeutics、Brooklyn ImmunoTherapeutics、Fueum CDI、Citius Pharmaceuticals和Kiji Therapeutics。

此外，ClinicalTrials.gov网站列出了超过1,670项涉及间质干细胞（MSCs）的临床试验。其中约75%（四分之三）的临床研究将MSCs用于再生医学（RM）产品的开发。约14%的研究将MSCs用于疾病建模。其余11%的研究将MSCs用于药物发现和细胞毒性测试。

这些试验面临的挑战包括在生长过程中维持间质干细胞的表型和功能。然而，由于持续的进展，未来前景光明，预计到2040年，全球至少将有50种基于间质干细胞的产品核准，平均每年新核准。

MSC研究产品领域的主要企业

近年来，对使用间质干细胞（MSCs）的研究产品的需求激增，促使领先的供应商扩展其产品线。像RoosterBio这样的公司正在透过工业化的供应链、标准化的细胞库产品形式以及符合cGMP规范的专用细胞和培养基系统，扩大高品质MSCs的取得途径。

其他主要的 MSC 研究产品供应商包括 PromoCell、Lonza、Thermo Fisher Scientific、STEMCELL Technologies、Miltenyi Biotec、Bio-Techne (R&D Systems)、ScienCell Laboratory 和 ATCC。

挑战与机会

儘管间质干细胞的商业化面临规模化生产和监管核准等诸多挑战，但也蕴藏着许多机会。基于间质干细胞的产品市场预计将在科研、治疗、化妆品和食品等行业中显着成长。

在这个瞬息万变的环境中，充分了解你的竞争对手至关重要。

这份全球策略报告介绍了与间质干细胞（MSCs）相关的临床试验数据、科学出版物、专利、资金筹措案例和合作趋势。报告还重点展示了基于MSCs的治疗产品线，分析了市场机会和挑战，并探讨了未来的发展方向和新兴应用领域。此外，报告还着重介绍了125家领先竞争对手提供的创新MSC产品、服务和技术。最后，该报告提供了全球MSC市场的详细市场规模数据，并按地区和业务部门进行了细分，同时对2031年之前的市场进行了预测。

目录

第一章：报告概述

  • 报告内容
  • 目标受众
  • 本报告的资讯来源
  • 报告目标
    • 研究领域的最新进展
    • 概述全球MSC市场。
    • 获得商业化机会
    • 确定主要市场参与企业并评估竞争格局。
    • 识别现有趋势和新趋势
    • 识别MSC市场中的关键机会与威胁。
  • 执行摘要
  • 介绍

第二章间质干细胞（MSCs）：概述

  • 人类间质干细胞（hMSCs）稳定化技术
  • 间质干细胞对再生医学的影响
  • MSC命名法时间表
  • MSC的供应来源
    • 骨髓间质间质干细胞（BM-MSCs）
    • 脂肪来源间质间质干细胞（AD-MSCs）
    • 脐带间间质干细胞（UC-MSCs）
    • iPSC衍生的间质干细胞（iMSCs）
  • 间间质干细胞的细胞表面标誌物
  • 间质干细胞的体外分化潜能
  • 间质干细胞分泌的可溶性因子
  • 间质干细胞
  • 间质干细胞的类型及其生物医学应用
  • 对间质干细胞特性至关重要的基因

第三章：间质干细胞临床试验的现状

  • 利用间质干细胞进行区域临床研究
  • 目前临床试验中使用的间质干细胞来源
  • 自体和异体间质干细胞在临床试验中的占比
  • 基于MSC的临床试验依疾病适应症分类。
  • 基于MSC的临床试验（依研究阶段划分）
  • 选择一项使​​用MSC的临床试验
    • 利用间质干细胞治疗肌肉骨骼疾病的临床试验
    • 利用间质干细胞治疗神经系统疾病的临床试验
    • 利用间质干细胞来源外泌体的临床试验
    • 临床试验中的预处理间质干细胞
    • 利用支架型间质干细胞的临床试验

第四章 间间质干细胞（MSCS）：专利趋势

  • MSC专利公开资讯（依管辖区划分）
  • MSC专利申请人
  • MSC专利发明人
  • MSC专利持有人
  • MSC专利申请的法律地位
  • 与MSC衍生外泌体相关的专利
  • 与iPSC衍生MSC（iMSC）相关的专利
  • MSC专利按治疗类型分类

第五章：已发表的MSCS科学论文

  • PubMed.gov 上发表的关于 MSC 在细胞治疗中应用的文章
  • 一篇发表在PubMed.gov上的关于基于MSC的免疫疗法的论文
  • 一篇关于间质干细胞在基因治疗应用的论文发表在PubMed.gov网站上。
  • 一篇关于间质干细胞在组织工程中应用的论文发表在PubMed.gov网站上。
  • PubMed.gov 上发表的关于 MSCs 在美容医学中应用的文章
  • 关于间质干细胞在主要疾病中应用的已发表论文数量
  • 关于改进型MSC的出版品
  • 已发表的关于MSC衍生外泌体的论文

第六章：MSC製造平台：概述

  • 分离间质干细胞的方法
  • 细胞增殖：从传统培养到生物反应器
    • 单层培养系统
    • 利用生物反应器进行细胞增殖
    • 目前正在使用的生物反应器
    • MSC扩展系统：概述
    • 以技术计算的每批次细胞计数
    • 用于细胞增生的微载体
  • MSC的下游工艺
    • 细胞脱离和分离（收穫）
    • 细胞洗涤和浓缩
    • 安全性和有效性测试
    • 区分间质干细胞和纤维母细胞的表面标誌物
  • 自製均质MSC生产：比较
    • 同种异体间质干细胞的生产成本
    • 内部生产MSC的成本
    • 捐赠者筛检和检测的费用
    • 发布测试成本
  • MSC的大规模生产
    • MSC製造平台
    • 扩大细胞培养容器的规模
    • 培养基
    • 间质干细胞的冷冻保存

第七章 细胞和基因疗法的契约製造

  • 人员短缺
  • 对自动化的需求
  • 容量限制
  • 一个潜力较大的CDMO平台
  • CMO/CDMO
    • 受託製造厂商（CMO）
    • 受託製造厂商（CDMO）
  • 製造设施的地理分布
  • 外包业务的持续成长
  • 美国主要CDMO（药品契约製造开发组织）
  • 欧洲领先的细胞和基因治疗CDMO
  • 英国在欧洲契约製造领域的统治地位

第八章：提升间质干细胞功能的生物工程解决方案

  • 间间质干细胞的低分子量预处理
  • MSC粒子工程
  • MSC基因工程
  • 利用生物工程改造的间质干细胞生产抗癌药物的实例
  • 用于治疗神经系统疾病的基因修饰间质干细胞
  • 基因工程改造的间质干细胞用于治疗心血管疾病
  • 间质干细胞治疗肺损伤
  • 基因改造的间质干细胞用于治疗糖尿病
  • 利用生物工程方法改善间质干细胞给药

第九章：MSCS 针对的主要疾病

  • 利用间质干细胞治疗自体免疫疾病的研究
  • 利用间质干细胞治疗心血管疾病的研究
  • 利用间质干细胞治疗神经退化性疾病的研究
  • 利用间质干细胞治疗骨骼和软骨疾病的研究
  • 利用间质干细胞治疗移植物抗宿主疾病的研究
  • 利用间质干细胞治疗克隆氏症的研究
  • 利用间质干细胞治疗第1型糖尿病的研究
  • 利用间质干细胞（MSCs）治疗全身性红斑性狼疮（SLE）的研究
  • 利用间质干细胞治疗帕金森氏症的研究
  • 利用间质干细胞治疗阿兹海默症的研究
  • 利用间质干细胞治疗肾衰竭的研究
  • 利用间质干细胞治疗脊髓损伤的研究
  • 利用间质干细胞进行创伤治疗的研究

第十章：MSC领域近期合作（2020-2024）

  • BioSolution Designs 与 RoosterBio 建立合作关係
  • CytoMed Therapeutics有限公司与盛港综合医院建立合作关係
  • REPROCELL 与 Histocell 的合作关係
  • 富士软片Diosynth与RoosterBio建立合作关係
  • RoosterBio与AGC Biologics的合作
  • RoosterBio与ShiftBio的合作
  • RoosterBio与Univercells Technologies的合作
  • Cynata与富士软片的合作关係
  • 美国 CryoStem 公司与 BioTherapeutic Lab 公司建立合作关係
  • RoosterBio与Sartorius的合作关係
  • 美国冷冻干细胞公司与合作研发协议
  • RoosterBio与Sartorius Korea Biotech达成合作
  • Catalent与BrainStorm的合作关係
  • 西普拉和史泰普蒂克斯的合作关係
  • Aethlon与匹兹堡大学的合作
  • RoosterBio与Senti Biosciences的合作

第十一章：全球市场中的MSC基产品

  • 核准干细胞疗法
    • 女王牢房
    • Cellgram AMI
    • 库皮斯特姆
    • 邪教
    • NeuroNataR
    • 全息
    • 原始基材/ Lionsil (Remestemcell-L)
    • 坦塞尔高中
    • 斯滕·皮尤塞尔
    • MesestroCell
    • 斯替米拉克
    • Royboshen（Amimestrocell）
  • 市售生物材料基间质干细胞及间质干细胞前驱细胞
    • Osteocel
    • AlloStem
    • Grafix
    • Cellentra VCBM
    • Trinity ELITE
    • Map3
    • BIO4
    • Trinity Evolution
    • Carticel
    • Chondron
    • DeNovo NT
    • Ossron
    • JACC
    • MACI
    • Ortho-ACI
    • Ossgrow
    • Cartigrow
  • 含有间质干细胞/间质干细胞衍生外泌体的局部用化妆品

第十二章 市场分析

  • MSC疗法的市场规模
  • 全球对间质干细胞（MSCs）的需求

第十三章：公司简介

  • Advancells
  • Aegle Therapeutics
  • AGC Biologics
  • AlloSource, Inc.
  • Ambulero
  • American CryoStem Corporation
  • American Type Culture Collection (ATCC)
  • Amniotics
  • Andelyn Biosciences
  • Anemocyte Srl
  • Anterogen, Co., Ltd.
  • Avid Bioservices, Inc.
  • Bacthera
  • Baylx, Inc.
  • BioCardia
  • BioCentriq
  • BioEden, Inc.
  • Bioinova sro
  • BioRestorative Therapies
  • Bioscience Institute SpA
  • Blue Horizon International, LLC
  • Boehringer Ingelheim BioXellence
  • Bonus Biogroup, Ltd.
  • BrainStorm Cell Therapeutics, Inc.
  • Catalent
  • CCRM
  • Cell2Cure ApS
  • Cell Care Therapeutics
  • Cellcolabs
  • CELLeBRAIN
  • Cellipont Bioservices
  • Celprogen, Inc.
  • CellProthera
  • CellResearch Corporation, Pte, Ltd.
  • Cell Surgical Network (CSN)
  • Celltex Therapeutics Corporation
  • CellTherapies
  • Cellular Biomedicine Group
  • Charles River Laboratories
  • CHIESI Farmaceutici SpA
  • Citius Pharmaceuticals, Inc.
  • CorestemChemon, Inc.
  • Creative Bioarray
  • Creative Medical Technology Holdings, Inc.
  • Curia Global, Inc
  • Cynata Therapeutics, Ltd
  • Cytovance Biologics
  • Defined Bioscience, Inc.
  • Direct Biologics
  • eQcell, Inc.
  • Excellos
  • Exosla Therapeutics
  • EXOSOMEplus
  • Exothera
  • Fujifilm Diosynth Biotechnologies
  • Future Cell Japan, Co., Ltd
  • Genezen
  • GenScript Biotech Corporation
  • Hope Biosciences, LLC
  • Implant Therapeutics, Inc
  • INCELL Corporation LLC
  • InGeneron GmbH
  • Invitrx Therapeutics
  • Japan Tissue Engineering, Co., Ltd. (J-TEC)
  • JCR Pharmaceuticals, Co., Ltd.
  • Jointechlabs
  • Kangstem Biotech, Co., Ltd
  • Kimera Labs
  • LifeCell
  • Longeveron
  • Lonza Group, Ltd
  • Lorem Cytori USA, Inc.
  • MEDPOST
  • Mesoblast, Ltd.
  • Millipore Sigma
  • NecstGen
  • NextCell
  • NIPRO Corporation
  • Novadip Biosciences
  • Novus Biologicals, LLC
  • NuVasive
  • OCT Therapies & Research Pvt., Ltd
  • OmniaBio, Inc.
  • Orthocell, Ltd
  • Orthofix Medical, Inc.
  • Ossium Health
  • Personal Cell Sciences Corporation
  • Personalized Stem Cells, Inc.
  • Pfizer CentreOne
  • Pluri Biotech, Ltd.
  • Porton Advanced
  • Prometheus Life Technologies
  • PromoCell GmbH
  • PuREC, Co., Ltd.
  • Regrow Biosciences
  • Reliance Life Sciences, Pvt., Ltd.
  • Remedy Cell, Ltd.
  • Rentschler Biopharma
  • REPROCELL USA, Inc
  • Resilence
  • RESTEM, LLC
  • RHEACELL GmbH &Co., KG
  • Richter-HELM
  • RoosterBio, Inc.
  • RTI Surgical
  • RoslinCT
  • Samsung Biologics
  • San Bio, Co., Ltd.
  • Smith & Nephew, Inc.
  • StemBioSys, Inc.
  • STEMCELL Technologies, Inc
  • Stemedica Cell Technologies, Inc.
  • Stemmatters
  • StemMedical
  • Stempeutics Research Pvt., Ltd
  • StromaBio AB
  • TaiwanBio Therapeutics, Co., Ltd.
  • Takeda Pharmaceutical, Co., Ltd
  • Tempo Bioscience
  • ThermoFisher Scientific
  • Vericel Corporation
  • Wuxi App Tec
  • Xintela AB

插图索引

表格一览

简介目录

EXECUTIVE SUMMARY

MSCs are multipotent cells that have been referred to as mesenchymal stem cells, medicinal signaling cells, and mesenchymal stromal cells, reflecting their versatility and diverse applications. MSCs can differentiate into a variety of cell types, such as osteoblasts, chondrocytes, myocytes, and adipocytes. Their unique ability to secrete factors that promote tissue repair and modulate their microenvironment with anti-inflammatory and anti-fibrotic effects makes them essential in regenerative medicine. Furthermore, their immuno-evasive properties make MSCs particularly suitable for allogenic transplantation.

MSCs serve as vital raw materials across numerous industries, including regenerative medicine, cosmeceuticals, and cultured meat production. Key applications include:

  • Cell-based therapies for musculoskeletal diseases, spinal injuries, and cardiovascular conditions.
  • Engineered tissues and organs, such as skin, bone, blood vessels, and liver.
  • Cell-derived products, such as exosomes and growth factors, utilized in cosmetics and skincare.
  • Cultured meat production, leveraging MSCs' role in muscle development and their ability to differentiate into muscle and fat cells.

Globally, 12 MSC-based therapies have been approved for various indications, with the majority concentrated in South Korea, Japan, and the EU.

Specifically, the Republic of Korea has approved five products: Queencell from Anterogen, Cellgram AMI from Pharmicell, Cupistem from Anterogen, Cartistem from Medipost, and NeuroNataR from Corestem. Japan has approved two products: Temcell HS from JCR Pharmaceuticals and Stemirac from Nipro Corporation. The EMA in Europe has approved two products: Holoclar from Chiesi Farmaceutici and Alofisel from TiGenix/Takeda. India has approved one product: Stempeucel from Stempeutics. Iran has approved one product: MesestroCell developed by Cell Tech Pharmed. Finally, Australia has approved one product: Remestemcel-L from Mesoblast.

Despite this progress, no MSC-based therapeutic have yet received U.S. FDA approval, although the FDA is actively reviewing Mesoblast's Remestemcel-L.

The cosmeceutical market is also rapidly adopting MSC-derived products, particularly exosomes, to leverage their anti-aging and regenerative properties, with companies like L'Oreal and Johnson & Johnson investing heavily in this space. Similarly, cultured meat companies are utilizing MSCs for producing muscle and fat cells, enhancing taste and texture. Groundbreaking approvals, such as lab-grown chicken by Upside Foods and Good Meat, have paved the way for further growth in this industry.

MSC-based gene editing is expanding, enabling the overexpression of antitumor genes and therapeutic factors. Researchers are also exploring the use of MSCs in 3D printing and engineered organ production, with breakthroughs anticipated in the next decade.

Importantly, companies like Cynata Therapeutics are pioneering iPSC-derived MSC production technologies, enabling large-scale therapeutic development. Today there are at least eight companies who are involved with the development of iPSC-derived MSCs therapeutics (iMSCs), including Cynata Therapeutics, Eterna Therapeutics, Implant Therapeutics, Bone Therapeutics, Brooklyn ImmunoTherapeutics, Fujifilm CDI, Citius Pharmaceuticals, and Kiji Therapeutics.

There are also over 1,670 clinical trials involving MSCs are registered on ClinicalTrials.gov. Nearly 75% (three-quarters) of these clinical studies are using MSCs for the development of regenerative medicine (RM) products. Approximately 14% of the studies are using MSCs for disease modeling. The remaining 11% of the studies are using MSCs for drug discovery and cytotoxicity testing applications.

Challenges in these trials include maintaining MSC phenotype and functionality during expansion. However, ongoing advancements suggest a promising future, with projections for at least 50 globally approved MSC-based products by 2040, averaging 3-4 new approvals annually.

Key Players in MSC Research Products

The demand for MSC-based research products has surged in recent years, with major suppliers expanding their portfolios. Companies like RoosterBio have increased the access to quality MSCs through supply chain industrialization, standardized cell bank product forms, and fit-for-purpose cGMP-compatible cells and media systems.

Other leading MSC research product suppliers include PromoCell, Lonza, Thermo Fisher Scientific, STEMCELL Technologies, Miltenyi Biotec, Bio-Techne (R&D Systems), ScienCell Research Laboratories, and the ATCC.

Challenges and Opportunities

While MSC commercialization faces hurdles-such as scalability and regulatory approval-opportunities abound. The market for MSC-based products is poised for notable growth across the research, therapeutic, cosmetic, and food industries.

Within this rapidly changing landscape, having a thorough understanding of the competition is essential.

This global strategic report presents rates of MSC clinical trials, scientific publications, patents, funding events, and collaborations. It presents the pipeline for MSC-based therapeutics, identifies market opportunities and threats, and explores future directions and emerging applications. It reveals innovative MSC products, services, and technologies offered by 125 leading competitors. Finally, it presents detailed market size figures for the global MSC market, segmented by geography and business segment with future forecasts through 2031.

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1 Statement of the Report
  • 1.2 Target Demographic
  • 1.3 Sources for this Report
  • 1.4 Purpose of the Report
    • 1.4.1 Survey Recent Advancements
    • 1.4.2 Provide a Summary of the Global MSC Market
    • 1.4.3 Access Opportunities for Commercialization
    • 1.4.4 Identify Major Market Players and Evaluate the Competitive Environment
    • 1.4.5 Identify Existing and Emerging Trends
    • 1.4.6 Identify Critical Opportunities and Threats within the MSC Market
  • 1.5 Executive Summary
  • 1.6 Introduction

2. MESENCHYMAL STEM CELLS (MSCs): AN OVERVIEW

  • 2.1 Stabilization of Human MSCs (hMSCs) as a Technology
  • 2.2 The Impact of MSCs on Regenerative Medicine
  • 2.3 Timeline of MSC Nomenclature
  • 2.4 Sources of MSCs
    • 2.4.1 Bone Marrow-Derived MSCs (BM-MSCs)
    • 2.4.2 Adipose-Derived MSCs (AD-MSCs)
    • 2.4.3 Umbilical Cord-Derived MSCs (UC-MSCs)
    • 2.4.4 iPSC-Derived MSCs (iMSCs)
  • 2.5 Cell Surface Markers in MSCs
  • 2.6 In vitro Differentiation Potentials of MSCs
  • 2.7 Soluble Factors Secreted by MSCs
  • 2.8 Stemness Genes Present in MSCs
  • 2.9 Types of MSCs and their Biomedical Applications
  • 2.10 Genes that are Pivotal for MSCs' Properties

3. MSC-BASED CLINICAL TRIAL LANDSCAPE

  • 3.1 MSC-Based Clinical Studies by Geography
  • 3.2 Sources of MSCs used in Current Clinical Trials
  • 3.3 Share of Autologous & Allogeneic MSCs Clinical Trials
  • 3.4 MSC-Based Clinical Trials by Disease Indication
  • 3.5 MSC-Based Clinical Trials by Phase of Study
  • 3.6 Select MSC-Based Clinical Trials
    • 3.6.1 MSC-Based Clinical Trials for Musculoskeletal Disorders
    • 3.6.2 MSC-Based Clinical Trials for Neurological Disorders
    • 3.6.3 Clinical Trials involving MSC-Derived Exosomes
    • 3.6.4 Primed MSCs in Clinical Trials
    • 3.6.5 Clinical Trials involving Scaffold-Based MSCs

4. MESENCHYMAL STEM CELLS (MSCS): PATENT LANDSCAPE

  • 4.1 MSC Patent Publications by Jurisdiction
  • 4.2 MSC Patent Applicants
  • 4.3 MSC Patent Inventors
  • 4.4 MSC Patent Owners
  • 4.5 Legal Status of MSC Patent Applications
  • 4.6 MSC-Derived Exosome Patents
    • 4.6.1 MSC-Derived Exosome Patents by Jurisdiction
    • 4.6.2 MSC-Derived Exosome Patent Applicants
    • 4.6.3 MSC-Derived Exosome Patent Inventors
    • 4.6.4 MSC-Derived Exosome Patent Owners
    • 4.6.5 Legal Status of MSC-Derived Exosome Patents
  • 4.7 Patents for iPSC-Derived MSCs (iMSCs)
    • 4.7.1 iPSC-Derived MSC Patents by Jurisdiction
    • 4.7.2 iPSC-Derived MSC Patent Owners
  • 4.8 MSC Patents by Therapy Type

5. PUBLISHED SCIENTIFIC PAPERS ON MSCS

  • 5.1 PubMed.gov Published Papers on MSCs in Cell Therapy
  • 5.2 PubMed.gov Published Papers on MSC-Based Immunotherapies
  • 5.3 PubMed.gov Published Papers on MSCs in Gene Therapy
  • 5.4 PubMed.gov Published Papers on MSCs in Tissue Engineering
  • 5.5 PubMed.gov Published Papers on MSCs in Aesthetics
  • 5.6 Number of Published Papers on the Applications of MSCs in Major Diseases
  • 5.7 Published Papers on Modified MSCs
  • 5.8 Published Papers on MSC-Derived Exosomes

6. MSC MANUFACTURING PLATFORMS: AN OVERVIEW

  • 6.1 Methods of Isolations of MSCs
  • 6.2 Cell Expansion: Conventional Cultures to Bioreactors
    • 6.2.1 Monolayer Culture Systems
    • 6.2.2 Bioreactor-Based Cell Expansion
      • 6.2.2.1 Stirred Tank Bioreactor
      • 6.2.2.2 Rocking Bioreactor
      • 6.2.2.3 Hollow Fiber Bioreactors
      • 6.2.2.4 Fixed-Bed Bioreactor
    • 6.2.3 Bioreactors in Current Use
      • 6.2.3.1 Automated Platforms
      • 6.2.3.2 Miniaturized Bioreactors
      • 6.2.3.3 Verical-Wheel Bioreactors
    • 6.2.4 MSC Expansion Systems: A Snapshot
    • 6.2.5 Number of Cells per batch by Technologies
    • 6.2.6 Microcarriers used for Cell Expansion
  • 6.3 Downstream Processing of MSCs
    • 6.3.1 Cell Detachment and Separation (Harvesting)
    • 6.3.2 Cell Washing and Concentration
    • 6.3.3 Safety and Potency Assays
    • 6.3.4 Surface Markers for Distinguishing MSCs from Fibroblasts
  • 6.4 Autologous & Allogeneic MSC Manufacturing: A Comparison
    • 6.4.1 Cost of Manufacturing Allogeneic MSCs
    • 6.4.2 Cost of Manufacturing Autologous MSCs
    • 6.4.3 Cost of Donor Screening & Testing
    • 6.4.4 Cost of Release Testing
  • 6.5 Large Scale Manufacturing of MSCs
    • 6.5.1 MSC Manufacturing Platforms
      • 6.5.1.1 Quantum Cell Expansion System
      • 6.5.1.2 CliniMACS Prodigy
      • 6.5.1.3 NANT 001
      • 6.5.1.4 CellQualia
      • 6.5.1.5 Cocoon
      • 6.5.1.6 Xuri Cell Expansion System W25
    • 6.5.2 Scaling Up of Cell Culture Vessels
      • 6.5.2.1 CellSTACK Multilayered Flasks
      • 6.5.2.2 Nunc Cell Factory Systems
      • 6.5.2.3 HYPERFlask Vessels
      • 6.5.2.4 HYPERStack
      • 6.5.2.5 CellCube System
    • 6.5.3 Culture Medium
      • 6.5.3.1 Expansion Ratios Achieved with Different Culture Media
    • 6.5.4 Cryopreservation of MSCs

7. CELL & GENE THERAPY CONTRACT MANUFACTURING

  • 7.1 Staff Shortage
  • 7.2 Need for Automation
  • 7.3 Capacity Constraints
  • 7.4 CDMO Platforms with Greater Potentials
    • 7.4.1 Type of CDMOs Used by Sponsors
  • 7.5 CMOs/CDMOs
    • 7.5.1 Contract Manufacturing Organizations (CMOs)
      • 7.5.1.1 Major Services Offered by CMOs
    • 7.5.2 Contract Development and Manufacturing Organizations (CDMOs)
      • 7.5.2.1 Major CDMOs
      • 7.5.2.2 Major Services offered by CDMOs
  • 7.6 Geographic Distribution of Manufacturing Facilities
  • 7.7 Continued Rise of Outsourcing
    • 7.7.1 Specific Areas of Outsourcing
    • 7.7.2 Select Services for Outsourcing
    • 7.7.3 Expected Rate of Outsourcing Increase
  • 7.8 Major CDMOs in the U.S.
  • 7.9 Major Cell & Gene Therapy CDMOs in Europe
  • 7.10 UK's Dominance in European Contract Manufacturing
    • 7.10.1 GMP Manufacturing in U.K.
    • 7.10.2 Cleanroom Footprint in UK
    • 7.10.3 Cell Therapy Process Capabilities in U.K.
    • 7.10.4 U.K.'s Gene Therapy Process Capabilities
    • 7.10.5 Future CDMO Capacity and Expansion within the UK

8. BIOENGINEERING SOLUTIONS TO BOOST MSC FUNCTIONALITY

  • 8.1 Small Molecule Priming of MSCs
  • 8.2 Particle Engineering of MSCs
    • 8.2.1 Materials used in Microparticles (MPs) Fabrication
  • 8.3 Genetic Engineering of MSCs
    • 8.3.1 Engineered MSCs as Living Drug Factories
  • 8.4 Examples of Bioengineered MSCs to Produce Anticancer Therapeutics
  • 8.5 Engineered MSCs for Neurological Conditions
  • 8.6 Engineered MSCs for Cardiovascular Diseases
  • 8.6 Engineered MSCs for Lung Injury
  • 8.7 Engineered MSCs for Diabetes
  • 8.8 Bioengineering Approaches to Improve MSC Administration

9. MAJOR DISEASES ADDRESSED BY MSCS

  • 9.1 Studies Using MSCs for Autoimmune Diseases
  • 9.2 Studies using MSCs for Cardiovascular Diseases
  • 9.3 Studies using MSCs for Neurodegenerative Diseases
  • 9.4 Studies using MSCs for Bone & Cartilage Diseases
  • 9.5 Studies using MSCs in GvHD
  • 9.6 Studies using MSCs in Crohn's Disease
  • 9.7 Studies using MSCs in Type 1 Diabetes
  • 9.8 Studies using MSCs in Systemic Lupus Erythematosus (SLE)
  • 9.9 Studies using MSCs in Parkinson's Disease
  • 9.10 Studies using MSCs in Alzheimer's Disease
  • 9.11 Studies using MSCs in Kidney Failure
  • 9.12 Studies using MSCs in Spinal Cord Injury
  • 9.13 Studies using MSCs for Wound Healing

10. RECENT COLLABORATIONS WITHIN THE MSC SECTOR, 2020-2024

  • 10.1 Collaboration between BioSolution Designs & RoosterBio
  • 10.2 Collaboration between CytoMed Therapeutics, Ltd. & Sengkang General Hospital
  • 10.3 Collaboration between REPROCELL & Histocell
  • 10.4 Collaboration between FUJIFILM Diosynth & RoosterBio
  • 10.5 RoosterBio's Collaboration with AGC Biologics
  • 10.6 RoosterBio's Partnership with ShiftBio
  • 10.7 RoosterBio's Partnership with Univercells Technologies
  • 10.8 Collaboration between Cynata & Fujifilm
  • 10.9 Collaboration between American CryoStem Corp. & BioTherapeutic Lab Corp.
  • 10.10 RoosterBio's Collaboration with Sartorius
  • 10.11 Collaboration between American CryoStem and CRADA
  • 10.12 RoosterBio's Collaboration with Sartorius Korea Biotech
  • 10.13 Collaboration between Catalent & BrainStorm
  • 10.14 Collaboration between Cipla & Stempeutics
  • 10.15 Aethlon's Collaboration with University of Pittsburgh
  • 10.16 RoosterBio's Collaboration with Senti Biosciences

11. MSC-BASED PRODUCTS IN THE GLOBAL MARKET

  • 11.1 Approved MSC Therapies
    • 11.1.1 Queencell
    • 11.1.2 Cellgram AMI
    • 11.1.3 Cupistem
    • 11.1.4 Cartistem
    • 11.1.5 NeuroNataR
    • 11.1.6 Holoclar
    • 11.1.7 Prochymal / Ryoncil (remestemcel-L)
    • 11.1.8 Temcell HS
    • 11.1.9 Stempeucel
    • 11.1.10 MesestroCell
    • 11.1.11 Stemirac
    • 11.1.12 Ruibosheng (amimestrocel)
  • 11.2 Marketed Biomaterial Carrier-Based MSCs & MSC Progenitors
    • 11.2.1 Osteocel
    • 11.2.2 AlloStem
    • 11.2.3 Grafix
    • 11.2.4 Cellentra VCBM
    • 11.2.5 Trinity ELITE
    • 11.2.6 Map3
    • 11.2.7 BIO4
    • 11.2.8 Trinity Evolution
    • 11.2.9 Carticel
    • 11.2.10 Chondron
    • 11.2.11 DeNovo NT
    • 11.2.12 Ossron
    • 11.2.13 JACC
    • 11.2.14 MACI
    • 11.2.15 Ortho-ACI
    • 11.2.16 Ossgrow
    • 11.2.17 Cartigrow
  • 11.3 Topical Cosmetic Products Containing MSCs/MSC-Derived Exosomes

12. MARKET ANALYSIS

  • 12.1 Market Size for MSC Therapies
  • 12.2 Global Demand for Mesenchymal Stem Cells (MSCs)
    • 12.2.1 Global Demand for MSCs in Academic and Preclinical Studies
    • 12.2.2 Global Demand for MSCs in Clinical Trials
    • 12.2.3 Global Demand for MSCs for Developing MSC Therapeutics
    • 12.2.4 Global Demand for MSCs to Develop Exosome Products
    • 12.2.5 Global Demand for MSCs in Emerging Industries
    • 12.2.6 Global Market for Mesenchymal Stem Cells (MSCs)
    • 12.2.7 Global MSC Market by Application

13. COMPANY PROFILES

  • 13.1 Advancells
    • 13.1.1 MSC-Derived Exosome Therapy
  • 13.2 Aegle Therapeutics
    • 13.2.1 Dystrophic Epidermolysis Bullosa
    • 13.2.2 Burns/Scarring
    • 13.2.3 Additional Indications
  • 13.3 AGC Biologics
    • 13.3.1 Cell Therapy Manufacturing
    • 13.3.2 Services
  • 13.4 AlloSource, Inc.
    • 13.4.1 Allografts with Tissue-Derived MSCs
    • 13.4.2 Products
      • 13.4.2.1 AlloConnex
      • 13.4.2.2 AlloFuse & AlloFuse Plus DBM
      • 13.4.2.3 AlloFlex Plus
      • 13.4.2.4 AlloFuse Cervical Grafts
      • 13.4.2.5 AlloFuse Fiber and Fiber Boats
      • 13.4.2.6 AlloFuse Select CM
  • 13.5 Ambulero
    • 13.5.1 Supercharged MSCs
    • 13.5.2 Ambulero's Pipeline
  • 13.6 American CryoStem Corporation
    • 13.6.1 Adult Stem Cell Storage Service
    • 13.6.2 Products Offered
      • 13.6.2.1 CELLECT
      • 13.6.2.2 ACSelerateMAX
      • 13.6.2.3 ATCELL
  • 13.7 American Type Culture Collection (ATCC)
    • 13.7.1 Stem Cell Products
  • 13.8 Amniotics
    • 13.8.1 Technology
    • 13.8.2 Product Pipeline
  • 13.9 Andelyn Biosciences
    • 13.9.1 Andelyn's Solutions
  • 13.10 Anemocyte S.r.l
    • 13.10.1 GMP Capacity
    • 13.10.2 Product Types
    • 13.10.3 Manufacturing Services
  • 13.11 Anterogen, Co., Ltd.
    • 13.11.1 Products
      • 13.11.1.1 Cupistem Injection
      • 13.11.1.2 Queencell
  • 13.12 Avid Bioservices, Inc.
    • 13.12.1 Services
  • 13.13 Bacthera
    • 13.13.1 Services
  • 13.14 Baylx, Inc.
    • 13.14.1 Technology
    • 13.14.2 Product Pipeline
      • 13.14.2.1 BX-U001 for Rheumatoid Arthritis
  • 13.15 BioCardia
    • 13.15.1 Product Pipeline
  • 13.16 BioCentriq
    • 13.16.1 Clinical Manufacturing Services
    • 13.16.2 Process Development Services
  • 13.17 BioEden, Inc.
  • 13.18 Bioinova s.r.o
    • 13.18.1 Products
    • 13.18.2 Services
      • 13.18.2.1 Storage & Transportation Solution
      • 13.18.2.2 Cryopreservation
      • 13.18.2.3 Autologous Therapy
      • 13.18.2.4 Allogeneic Therapy
  • 13.19 BioRestorative Therapies
    • 13.19.1 BRTX-100
    • 13.19.2 ThermoStem
  • 13.20 Bioscience Institute S.p.A
    • 13.20.1 Aesthetic Stem Cells
      • 13.20.1.1 LIPOSKILL for Skin Rejuvenation
      • 13.20.1.2 LIPOSKILL PLUS for Face Reshaping
      • 13.20.1.3 LIPOSKILL PLUS for Breast Augmentation
      • 13.20.1.4 LIPOSKILL PLUS for Buttock Enhancement
      • 13.20.1.5 LIPOSKILL PLUS for Reduction of Scars and Stretch Marks
      • 13.20.1.6 HAIRSKILL for Hair Loss Treatment
      • 13.20.1.7 GYNSKILL for Vulvo-Vaginal Rejuvenation
    • 13.20.2 Regenerative Stem Cells
      • 13.20.2.1 ORTHOSKILL for Regenerative Orthopedics
      • 13.20.2.2 OVOSKILL for Early Menopause Treatment
      • 13.20.2.3 ANDROSKILL for Erectile Dysfunction Treatment
      • 13.20.2.4 Anti-Aging IV Therapy
      • 13.20.2.5 XEROSTOMIA Treatment
      • 13.20.2.6 Empty Nose Syndrome (ENS) Treatment
      • 13.20.2.7 Stem Cell Therapy for Body Performance
  • 13.21 Blue Horizon International, LLC
    • 13.21.1 BHI's Stem Cell Division
  • 13.22 Boehringer Ingelheim BioXellence
    • 13.22.1 Services
  • 13.23 Bonus Biogroup, Ltd.
    • 13.23.1 BonoFill
    • 13.23.2 MesenCure
  • 13.24 BrainStorm Cell Therapeutics, Inc.
    • 13.24.1 NurOwn Technology
    • 13.24.2 Manufacturing of NurOwn
    • 13.24.3 BrainStorm's Clinical Trials
  • 13.25 Catalent
    • 13.25.1 Cell Therapy Process Development
    • 13.25.2 Cell Therapy CGMP Manufacturing
  • 13.26 CCRM
  • 13.27 Cell2Cure ApS
    • 13.27.1 Product
      • 13.27.1.1 Mode of Action
      • 13.27.1.2 Manufacture
  • 13.28 Cell Care Therapeutics
    • 13.28.1 Platform
    • 13.28.2 CCT-101
  • 13.29 Cellcolabs
    • 13.29.1 Ordering Cells
  • 13.30 CELLeBRAIN
    • 13.30.1 Core Technology
    • 13.30.2 CELLeBRAIN's Product Pipeline
  • 13.31 Cellipont Bioservices
    • 13.31.1 Cellipont's Capabilities
    • 13.33.2 Cellipont's Cell Expertise
  • 13.34 Celprogen, Inc.
    • 13.34.1 Products
    • 13.34.2 Services
  • 13.35 CellProthera
    • 13.35.1 ProtheraCytes
    • 13.35.2 Technology: StemXpand
  • 13.36 CellResearch Corporation, Pte, Ltd.
    • 13.36.1 Umbilical Cord Lining Stem Cells
    • 13.36.2 CALECIM
  • 13.37 Cell Surgical Network (CSN)
    • 13.37.1 Technology: The Time Machine 3.0 Auto
    • 13.37.2 Time Machine Process
  • 13.38 Celltex Therapeutics Corporation
    • 13.38.1 Therapy Services
  • 13.39 CellTherapies
    • 13.39.1 Services
    • 13.39.2 Contract Manufacturing
    • 13.39.3 Apheresis Management
    • 13.39.4 Clinical Trial Support
  • 13.40 Cellular Biomedicine Group
  • 13.41 Charles River Laboratories
    • 13.41.1 Cell Therapy Manufacturing Services
  • 13.42 CHIESI Farmaceutici S.p.A
    • 13.42.1 Holoclar
  • 13.43 Citius Pharmaceuticals, Inc.
    • 13.43.1 Stem Cell Platform
  • 13.44 CorestemChemon, Inc.
    • 13.44.1 Neuronata-R inj.
  • 13.45 Creative Bioarray
    • 13.45.1 MSC Services
    • 13.45.2 MSC Isolation and Expansion Services
    • 13.45.3 MSC Characterization Services
    • 13.45.4 MSC Differentiation Services
  • 13.46 Creative Medical Technology Holdings, Inc.
    • 13.46.1 Rapid Autologous Therapies
    • 13.46.2 Creative Medical's Preclinical and Clinical Pipeline
  • 13.47 Curia Global, Inc
    • 13.47.1 Services
  • 13.48 Cynata Therapeutics, Ltd.
    • 13.48.1 Cymerus Platform
      • 13.48.1.1 CYP-001
      • 13.48.1.2 CYP-004
      • 13.48.1.3 Cymerus MSCs for ARDS
      • 13.48.1.4 CYP-006TK
  • 13.49 Cytovance Biologics
    • 13.49.1 GMP Manufacturing
  • 13.50 Defined Bioscience, Inc.
    • 13.50.1 Products
      • 13.50.1.1 Applications in Stem Cells
      • 13.50.1.2 Applications in Cultivated Meat
  • 13.51 Direct Biologics
    • 13.51.1 ExoFlo
  • 13.52 eQcell, Inc.
    • 13.52.1 Innovation
  • 13.53 Excellos
  • 13.54 Exosla Therapeutics
  • 13.55 EXOSOMEplus
  • 13.56 Exothera
    • 13.56.1 Exoscan Process Analysis Services
    • 13.56.2 Process Design & Development Services
    • 13.56.3 GMP Manufacturing Services
  • 13.57 Fujifilm Diosynth Biotechnologies
    • 13.57.1 Cell & Gene Therapy Services
  • 13.58 Future Cell Japan, Co., Ltd.
    • 13.58.1 Conditioned Media from UC-MSCs
  • 13.59 Genezen
    • 13.59.1 Genezen's Capabilities
  • 13.60 GenScript Biotech Corporation
    • 13.60.1 Cell Therapy Product Solutions
      • 13.60.1.1 CytoSinct Nanobeads
      • 13.60.1.2 CytoSinct Manual Separator System
      • 13.60.1.3 CytoSinct 1000
  • 13.61 Hope Biosciences, LLC
    • 13.61.1 Adult Stem Cell Banking
    • 13.61.2 Newborn Stem Cell Banking
    • 13.61.3 Sponsored Clinical Trials
  • 13.62 Implant Therapeutics, Inc.
    • 13.62.1 Services
  • 13.63 INCELL Corporation LLC
    • 13.63.1 Product Line
    • 13.63.2 Cell & Tissue Products
    • 13.63.3 Tissue Collections & Kit Products
    • 13.63.4 Storage of Cell & Tissue Products
  • 13.64 InGeneron GmbH
    • 13.64.1 Transpose RT Process
    • 13.64.2 Adipose-Derived Regenerative Cells (ADRCs)
  • 13.65 Invitrx Therapeutics
    • 13.65.1 Reluma
  • 13.66 Japan Tissue Engineering, Co., Ltd. (J-TEC)
    • 13.66.1 JACC
  • 13.67 JCR Pharmaceuticals, Co., Ltd.
    • 13.67.1 TEMCELL HS Inj.
  • 13.68 Jointechlabs
    • 13.68.1 Products
      • 13.68.1.1 MiniTC
      • 13.68.1.2 Mini-Stem
    • 13.68.2 Jointech's Products in Pipeline
      • 13.68.2.1 JTL-T-01 (Osteoarthritis Clinical Therapy)
      • 13.68.2.2 JTL-T-02 (Wounds Clinical Therapy)
  • 13.69 Kangstem Biotech, Co., Ltd.
    • 13.69.1 Stem Cell Therapeutics
    • 13.69.2 Stem Cell Therapy
  • 13.70 Kimera Labs
    • 13.70.1 Vive
    • 13.70.2 Luxir
  • 13.71 LifeCell
    • 13.71.1 Large-Scale Manufacturing of MSCs
  • 13.72 Longeveron
    • 13.72.1 Lomecel-B
    • 13.72.2 Clinical Pipeline
  • 13.73 Lonza Group, Ltd
    • 13.73.1 Sell& Gene Technologies Segment
    • 13.73.2 Bioscience Segment
    • 13.73.3 Personalized Medicines Segment
  • 13.74 Lorem Cytori USA, Inc.
    • 13.74.1 Celution System
    • 13.74.2 Cytori Cell Therapy
  • 13.75 MEDPOST
    • 13.75.1 Products
      • 13.75.1.1 CARTISTEM
      • 13.75.1.2 PNEUMOSTEM
      • 13.75.1.3 SMUP-IA-01
      • 13.75.1.4 SMUP-IV-01
  • 13.76 Mesoblast, Ltd.
    • 13.76.1 Technology Platform
    • 13.76.2 Intellectual Property Estate
    • 13.76.3 Product Candidates
      • 13.76.3.1 Revascor
      • 13.76.3.2 MPC-06-ID
      • 13.76.3.3 Remestemcel-L
      • 13.76.3.4 MPC-300-IV
  • 13.77 Millipore Sigma
    • 13.77.1 Cell Culture & Analysis Products
  • 13.78 NecstGen
    • 13.78.1 Cell Therapy Development & Manufacturing
    • 13.78.2 Viral Vector Development & Manufacturing
    • 13.78.3 Cleanroom Rental
  • 13.79 NextCell
    • 13.79.1 ProTrans
    • 13.79.2 Cellaviva
    • 13.79.3 NextCell's Products in Pipeline
  • 13.80 NIPRO Corporation
    • 13.80.1 Stemirac
  • 13.81 Novadip Biosciences
    • 13.81.1 The 3M3 Platform
    • 3.81.2 Products
      • 13.81.2.1 3MAUTO
      • 13.81.2.2 3MALLO
      • 13.81.2.3 3MEXO
  • 13.82 Novus Biologicals, LLC
  • 13.83 NuVasive
    • 13.83.1 Osteocel Portfolio
      • 13.83.1.1 Osteocel Plus
      • 13.83.1.2 Osteocel Pro
  • 13.84 OCT Therapies & Research Pvt., Ltd
  • 13.85 OmniaBio, Inc.
    • 13.85.1 Services
      • 13.85.1.1 Process Development
      • 13.85.1.2 GMP Manufacturing
      • 13.85.1.3 Analytical Development
      • 13.85.1.4 Regulatory Guidance
  • 13.86 Orthocell, Ltd.
    • 13.86.1 OrthoACI
  • 13.87 Orthofix Medical, Inc.
    • 13.87.1 Trinity Elite
    • 13.87.2 Trinity Evolution
  • 13.88 Ossium Health
    • 13.88.1 Platform
    • 13.88.2 Applications
      • 13.88.2.1 Hematologic Diseases
      • 13.88.2.2 Organ Transplant Rejection
      • 13.88.2.3 Musculoskeletal Defects
    • 13.88.3 Products
      • 13.88.3.1 OssiGraft Prime
      • 13.88.3.2 OssiGraft
      • 13.88.3.3 GMP Human Mesenchymal Stem Cells
      • 13.88.3.4 GMP Human Selected CD34+ Cells
      • 13.88.3.5 RUO Mesenchymal Stem Cells
      • 13.88.3.6 RUO Human Selected CD34+ Cells
  • 13.89 Personal Cell Sciences Corporation
    • 13.89.1 Autokine CM
    • 13.89.2 Products
  • 13.90 Personalized Stem Cells, Inc.
    • 13.90.1 Personalized Stem Cells for Knee Osteoarthritis
  • 13.91 Pfizer CentreOne
    • 13.91.1 Manufacturing
  • 13.92 Pluri Biotech, Ltd.
    • 13.92.1 PLX Products
  • 13.93 Porton Advanced
    • 13.93.1 Cell Therapy Services
    • 13.93.2 LVV Services
    • 13.93.3 PLX-PAD
    • 13.93.4 PLX-R18
    • 13.93.5 PLX-Immune
  • 13.94 Prometheus Life Technologies
    • 13.94.1 Organoids
  • 13.95 PromoCell GmbH
    • 13.95.1 Products
  • 13.96 PuREC, Co., Ltd.
    • 13.96.1 PuREC Solution for Hypophosphatasia
    • 13.96.2 PuREC Solution for Spinal Canal Stenosis
  • 13.97 Regrow Biosciences
    • 13.97.1 Ossgrow
    • 13.97.2 Cartigrow
  • 13.98 Reliance Life Sciences, Pvt., Ltd.
    • 13.98.1 Regenerative Medicine Products
  • 13.99 Remedy Cell, Ltd.
    • 13.99.1 Proprietary Platform
    • 13.99.2 Drug Candidate: RC-0315
  • 13.100 Rentschler Biopharma
    • 13.100.1 Services
  • 13.101 REPROCELL USA, Inc.
    • 13.101.1 Services
    • 13.101.2 Products
  • 13.102 Resilence
    • 13.102.1 Resilience's Capabilities
  • 13.103 RESTEM, LLC
    • 13.103.1 Umbilical Cord Lining Stem Cells (ULSCs)
    • 13.103.2 Muscular Dystrophy - Clinical Trial
    • 13.103.3 Dermatomyositis & Polymyositis - Clinical Trial
    • 13.103.3 Heart Failure - Clinical Trial
  • 13.104 RHEACELL GmbH & Co., KG
    • 13.104.1 Technology
    • 13.104.2 ABCB5+MSCs
  • 13.105 Richter-HELM
    • 13.105.1 Services
  • 13.106 RoosterBio, Inc.
    • 13.106.1 Technology
    • 13.106.2 Products
      • 13.106.2.1 Human Mesenchymal Stem Cells (hMSCs)
    • 13.106.3 Genetic Engineering Tools
      • 13.106.3.1 Genetic Engineering Media
    • 13.106.4 Cell Culture Media & Supplements
    • 13.106.5 Cell & Media Kits
    • 13.106.6 MSC-Derived Exosomes
    • 13.106.7 cGMP CliniControl Products
    • 13.106.8 Process Development Services
    • 13.106.9 hMSC Analytical Services
  • 13.107 RTI Surgical
    • 13.107.1 Map3
  • 13.108 RoslinCT
    • 13.108.1 Services
      • 13.108.1.1 Process Development
      • 13.108.1.2 GMP Manufacturing
      • 13.108.1.3 Quality Control
      • 13.108.1.4 Quality & Regulations
      • 13.108.1.5 Product Storage & Logistics
    • 13.108.2 RoslinCT-Lykan Bioscience Combine
  • 13.109 Samsung Biologics
    • 13.109.1 Contract Manufacturing Capabilities
  • 13.110 San Bio, Co., Ltd.
    • 13.110.1 SB623
  • 13.111 Smith & Nephew, Inc.
    • 13.111.1 Grafix
  • 13.112 StemBioSys, Inc.
    • 13.112.1 CELLvo Matrix Technology
    • 13.112.2 CELLVO hAD-MSCs
    • 13.112.3 CELLvo hBM-MSCs
    • 13.112.4 CELLvo hWJ-MSCs
    • 13.112.5 CELLvo Amniotic Membrane MSCs
  • 13.113 STEMCELL Technologies, Inc.
    • 13.113.1 Products
      • 13.113.1.1 MSC & MSC Progenitor Cell Research Products
  • 13.114 Stemedica Cell Technologies, Inc.
    • 13.114.1 BioSmart Technology
    • 13.114.2 Research & Development
  • 13.115 Stemmatters
  • 13.116 StemMedical
    • 13.116.1 Stemform Procedure
    • 13.116.2 Therapeutics Development
  • 13.117 Stempeutics Research Pvt., Ltd.
    • 13.117.1 Stempeucel
  • 13.118 StromaBio AB
    • 13.118.1 MSC Platform
  • 13.119 TaiwanBio Therapeutics, Co., Ltd.
  • 13.120 Takeda Pharmaceutical, Co., Ltd.
    • 13.120.1 Alofisel
  • 13.121 Tempo Bioscience
    • 13.121.1 Tempo iMSCs
  • 13.122 ThermoFisher Scientific
    • 13.122.1 CDMO Services for Cell Therapy
  • 13.123 Vericel Corporation
    • 13.123.1 MACI
  • 13.124 Wuxi App Tec
    • 13.124.1 CTDMO Services
  • 13.125 Xintela AB
    • 13.125.1 Technology Platform
    • 13.125.2 Stem Cell Products
      • 13.125.2.1 XSTEM
      • 13.125.2.2 EQSTEM
      • 13.125.2.3 Cancer Therapy

INDEX OF FIGURES

  • FIGURE 2.1: Mesenchymal Stem Cells and Their Derivatives
  • FIGURE 3.1: Number of Registered MSC-Based Clinical Trials, 1995- Jan, 2025
  • FIGURE 3.2: MSC-Based Clinical Trials by Region
  • FIGURE 3.3: MSC-Based Clinical Trials by Cell Source, Jan- 2025
  • FIGURE 3.4: Share of Autologous & Allogeneic MSCs in Clinical Trials
  • FIGURE 3.5: MSC-Based Clinical Trials by Indication
  • FIGURE 3.6: Percent Share of MSC-Based Clinical Trials by Phase of Study
  • FIGURE 4.1: MSC Patent Publications Over Time, 2000-Jan 7, 2025
  • FIGURE 4.2: MSC-Derived Exosome Patent Publications over Time
  • FIGURE 4.3: iPSC-Derived MSCs Patent Publications over Time
  • FIGURE 4.4: MSC Patents by Applications
  • FIGURE 5.1: Published Papers in PubMed.gov on Mesenchymal Stem Cells (MSCs)
  • FIGURE 5.2: PubMed.gov Published Papers on MSCs in Cell Therapy
  • FIGURE 5.3: PubMed.gov Published Papers on MSC-Based Immunotherapies
  • FIGURE 5.4: PubMed.gov Published Papers on MSCs in Gene Therapy
  • FIGURE 5.5: PubMed.gov Published Papers on MSCs in Tissue Engineering
  • FIGURE 5.6: PubMed.gov Published Papers on MSCs in Aesthetics
  • FIGURE 5.7: PubMed Published Papers on Major Ten Diseases addressed by MSCs
  • FIGURE 5.8: Number of Published Papers on Modified MSCs
  • FIGURE 5.9: Number of Published Papers on MSC-Derived Exosomes
  • FIGURE 6.1: Advantages and Disadvantages of Autologous & Allogeneic MSCs
  • FIGURE 6.2: Monolayer Culture Systems
  • FIGURE 6.3: Stirred Tank Bioreactor
  • FIGURE 6.4: Rocking Bioreactor or Wave Bioreactor
  • FIGURE 6.5: Hollow Fiber Bioreactor
  • FIGURE 6.6: Fixed-Bed Reactor
  • FIGURE 6.7: CompacT SelecT System from Sartorius
  • FIGURE 6.8: DASbox Mini Bioreactor System
  • FIGURE 6.9: PBS-80 Vertical-Wheel Bioreactor
  • FIGURE 6.10: Number of Cells per batch by Technologies
  • FIGURE 6.11: Overview of Bioprocessing Strategies for Large-Scale Production of MSCs
  • FIGURE 7.1: CDMO Platforms with Greater Potentials
  • FIGURE 7.2: Type of CDMOs Used by Sponsors
  • FIGURE 7.3: Major Services Offered by CMOs
  • FIGURE 7.4: Major Services used by Sponsors from CDMOs
  • FIGURE 7.5: Geographic Distribution of Manufacturing Facilities, 2017-2027
  • FIGURE 7.6: Percent Share of Outsourcing
  • FIGURE 7.7: Select Services for Outsourcing
  • FIGURE 7.8: Changing Priorities in Outsorcing Services between 2023 and 2025
  • FIGURE 7.9: Cleanroom Footprint in UK, 2018-2023
  • FIGURE 7.10: Cell Therapy Process Capabilities in U.K.
  • FIGURE 7.11: Gene Therapy Process Capabilities in U.K.
  • FIGURE 8.1: Bioengineering Solutions to Boost the Innate Functions of MSCs
  • FIGURE 8.2: Bioengineering Approaches to MSC Administration
  • FIGURE 9.1: Major Diseases Addresses by MSCs in Clinical Trials
  • FIGURE 9.2: Percentage Share of Autoimmune Diseases using MSCs in Clinical Trials
  • FIGURE 9.3: Percent Share of MSCs by Source in Trials for Cardiovascular Diseases
  • FIGURE 9.4: Percent Shares of Neurological Diseases in Clinical Trials using MSCs
  • FIGURE 9.5: Percent Shares of MSC-Based Musculoskeletal Studies by Source
  • FIGURE 12.1: Global Market for MSC-Based Therapeutics, 2023-2031
  • FIGURE 12.2: Global Market for Mesenchymal Stem Cells (MSCs)
  • FIGURE 12.3: Market Share of MSCs by Application
  • FIGURE 13.1: CELLeBRAIN's Core Technology
  • FIGURE 13.2: CALECIM
  • FIGURE 13.3: Schematic Diagram of CytoSinct Nanobeads
  • FIGURE 13.4: CytoSinct 1000
  • FIGURE 13.5: Why-iPSC Derived MSCs (iMSCs)
  • FIGURE 13.6: MiniTC
  • FIGURE 13.7: Mini-Stem

INDEX OF TABLES

  • TABLE 2.1: Timeline of MSC Nomenclature
  • TABLE 2.2: Sources of MSCs
  • TABLE 2.3: Advantages & Disadvantages of BM-MSCs
  • TABLE 2.4: Advantages & Disadvantages of AD-MSCs
  • TABLE 2.5: Advantages & Disadvantages of Umbilical Cord MSCs (UC-MSCs)
  • TABLE 2.6: Companies Developing iMSC Products
  • TABLE 2.7: Positive & Negative Markers in MSCs from Different Sources
  • TABLE 2.8: in vitro Differentiation Potentials of MSCs
  • TABLE 2.9: Soluble Factors Secreted by MSCs
  • TABLE 2.10: Some Typical "Stemness" Genes of MSCs
  • TABLE 2.11: Types of MSCs and their Biomedical Applications
  • TABLE 2.12: Genes that are Pivotal for MSCs' Properties
  • TABLE 3.1: MSC-Based Clinical Trials by Cell Source
  • TABLE 3.2: Select MSC-Based Clinical Trials
  • TABLE 3.3: Select MSC-Based Clinical Trials for Musculoskeletal Disorders
  • TABLE 3.4: Select MSC-Based Clinical Trials for Neurological Disorders
  • TABLE 3.5: Select Clinical Trials involving MSC-Derived Exosomes
  • TABLE 3.6: Primed MSCs in Clinical Trials
  • TABLE 3.7: Clinical Trials involving Scaffold-Based MSCs
  • TABLE 4.1: MSC Patent Records by Jurisdiction, January 7, 2025
  • TABLE 4.2: MSC Patent Applicants, January 7, 2025
  • TABLE 4.3: MSC Patent Inventors
  • TABLE 4.4: MSC Patent Owners
  • TABLE 4.5: Legal Status of MSC Patent Applications
  • TABLE 4.6: MSC-Derived Exosome Patents by Jurisdiction
  • TABLE 4.7: MSC-Derived Exosome Patent Applicants
  • TABLE 4.8: MSC-Derived Exosome Patent Inventors
  • TABLE 4.9: MSC-Derived Exosome Patent Owners
  • TABLE 4.10: Legal Status of MSC-Derived Exosome Patents
  • TABLE 4.11: iPSC-Derived MSC Patent Applications by Jurisdiction, August 2024
  • TABLE 4.12: iPSC-Derived MSC Patent Owners
  • TABLE 4.13: MSC Patents by Applications
  • TABLE 5.1: PubMed Published Papers on Major Ten Diseases addressed by MSCs
  • TABLE 5.2: Number of Published Papers on Modified MSCs
  • TABLE 5.3: Number of Published Papers on MSC-Derived Exosomes
  • TABLE 6.1: Methods of Isolations of MSCs
  • TABLE 6.2: A Snapshot of Commercially Available Culture Systems
  • TABLE 6.3: Microcarriers used for Cell Expansion
  • TABLE 6.4: Basic Assays for MSCs
  • TABLE 6.5: Cell Surface Markers on MSCs & Fibroblasts: A Comparison
  • TABLE 6.6: Cost of Manufacturing Allogeneic MSCs
  • TABLE 6.7: Cost of Manufacturing Autologous MSCs
  • TABLE 6.8: Media Used for GMP Grade MSC Production
  • TABLE 6.9: Expansion Ratios Achieved with Different Culture Media
  • TABLE 6.10: Commercially Available Controlled Freezing Systems for MSCs
  • TABLE 7.1: Top Ten CDMO Companies in 2003 & 2027
  • TABLE 7.2: GMP Capacities of U.S.-Based CDMOs
  • TABLE 7.3: GMP Capacities of European CDMOs
  • TABLE 7.4: MHRA-Licensed Manufacturing Facilities
  • TABLE 7.5: Cleanroom Footprint in UK, 2019-2023
  • TABLE 8.1: Examples of Priming Strategies in Animal Models
  • TABLE 8.2: Materials used in Microparticles (MPs) Fabrication
  • TABLE 8.3: Genetic Engineering Method used in MSCs
  • TABLE 8.4: Examples of Bioengineered MSCs as Living Drug Factories
  • TABLE 8.5: Examples of Oncology Indications being Studied using Engineered MSCs
  • TABLE 8.6: Effects of Engineered MSCs in Neurological Indications
  • TABLE 9.1: Select MSC-Based Clinical Trials for Autoimmune Diseases
  • TABLE 9.2: Select MSC-Based Clinical Trials for Cardiovascular Diseases
  • TABLE 9.3: Select MSC-Based Clinical Studies for Neurological Diseases
  • TABLE 9.4: Select MSC-Based Studies for Musculoskeletal Disorders
  • TABLE 9.5: Select Ongoing Studies using MSCs for GvHD
  • TABLE 9.6: Studies using MSCs in Crohn's Diseases
  • TABLE 9.7: Select Studies using MSCs in Type 1 Diabetes
  • TABLE 9.8: Select Studies using MSCs in Systemic Lupus Erythematosus (SLE)
  • TABLE 9.9: Select Studies using MSCs in Parkinson's Disease
  • TABLE 9.10: Select Ongoing Studies using MSCs in Alzheimer's Disease
  • TABLE 9.11: Select Ongoing Studies using MSCs in Kidney Failure
  • TABLE 9.12: Select Studies using MSCs in Spinal Cord Injury
  • TABLE 9.13: Select Studies using MSCs for Wound Healing
  • TABLE 11.1: Currently Available MSC Therapies
  • TABLE 11.2: Queencell - Product Information
  • TABLE 11.3: Cellgram AMI - Product Information
  • TABLE 11.4: Cupistem - Product Information
  • TABLE 11.5: Cartistem - Product Information
  • TABLE 11.6: NeuroNataR - Product Information
  • TABLE 11.7: Holoclar - Product Information
  • TABLE 11.8: Prochymal/Ryoncil (Remestemcel-L) - Product Information
  • TABLE 11.9: Temcell HS - Product Information
  • TABLE 11.10: Stempeucel - Product Information
  • TABLE 11.12: MesestroCell - Product Information
  • TABLE 11.13: Stemirac - Product Information
  • TABLE 11.14: Currently Marketed Biomaterial-Based MSCs & MSC Progenitors
  • TABLE 11.15: Osteocel - Product Information
  • TABLE 11.16: AlloStem - Product Information
  • TABLE 11.17: Grafix - Product Information
  • TABLE 11.18: Cellentra VCBM - Product Information
  • TABLE 11.19: Trinity ELITE - Product Information
  • TABLE 11.20: Map3 - Product Information
  • TABLE 11.21: Bio4 - Product Information
  • TABLE 11.22: Trinity Evolution - Product Information
  • TABLE 11.23: Carticel - Product Information
  • TABLE 11.24: Chondron - Product Information
  • TABLE 11.25: DeNovo NT - Product Information
  • TABLE 11.26: Ossron - Product Information
  • TABLE 11.27: JACC - Product Information
  • TABLE 11.28: MACI - Product Information
  • TABLE 11.29: Ortho-ACI - Product Information
  • TABLE 11.30: Ossgrow - Product Information
  • TABLE 11.31: Cartigrow - Product Information
  • TABLE 11.32: Commercially Available Skincare Cosmetics with MSC-Derived Exosomes
  • TABLE 12.1: Global Market for MSC-Based Therapeutics, 2024-2031
  • TABLE 12.2: Global Market for Mesenchymal Stem Cells (MSCs),2024-2031
  • TABLE 13.1: Aegle's Product Pipeline
  • TABLE 13.2: Ambulero's Product Pipeline
  • TABLE 13.3: Amniotics' Product Pipeline
  • TABLE 13.4: Baylx's Product Pipeline
  • TABLE 13.5: BioCardia's Product Pipeline
  • TABLE 13.6: Bonus Biogroup's Product Pipeline
  • TABLE 13.7: BrainStorm's Clinical Trials
  • TABLE 13.8: CELLeBRAIN's Product Pipeline
  • TABLE 13.9: CellProthera's Preclinical and Clinical Pipeline
  • TABLE 13.10: Celltex's Clinical Trials
  • TABLE 13.11: Corestem's Product Pipeline
  • TABLE 13.12: Creative Medical's Preclinical and Clinical Pipeline
  • TABLE 13.13: Regulatory Proteins found in ExoFlo
  • TABLE 13.14: Hopes Clinical Trial Pipeline using HB-adMSC
  • TABLE 13.15: Kangstem's Sponsor Initiated Clinical Trials
  • TABLE 13.16: Longeveron's Clinical Pipeline
  • TABLE 13.17: NextCell's Products in Pipeline
  • TABLE 13.18: Novadip's Product Pipeline
  • TABLE 13.19: RHEACELL's Products in Pipeline
  • TABLE 13.20: San Bio's Product Pipeline
  • TABLE 13.21: Stemedica's Product Pipeline
  • TABLE 13.22: Stempeutics' Product Development Status
  • TABLE 13.23: Xintela's Product Pipeline